# Kairos Pharma, LTD. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Kairos Pharma, LTD.). ## Overview Kairos Pharma, Ltd. is a U.S.-based clinical-stage pharmaceutical company focused on acquiring, licensing, and developing drug candidates and related intellectual property. The company has no approved products or product sales yet, and its current business is centered on preclinical and clinical development, IP portfolio building, and capital raising to fund operations. ## Products & services • Licensed drug-development programs from Cedars • NFkB/RelA-binding compound use methods • Fibrosis treatment compositions and methods • Preclinical and clinical drug development • Intellectual property licensing and portfolio development - **Licensed therapeutic programs** (0%) — Exclusive license rights to patented technologies and drug-development programs sourced from Cedars. - **Preclinical development** (45%) — Early-stage research, candidate selection, and nonclinical studies to advance product concepts. - **Clinical development** (35%) — Human clinical studies and related regulatory preparation for product candidates. - **Intellectual property and business development** (20%) — Patent portfolio management, licensing, and partnering activities that support commercialization. - Licensed drug-development programs from Cedars - NFkB/RelA-binding compound use methods - Fibrosis treatment compositions and methods - Preclinical and clinical drug development - Intellectual property licensing and portfolio development ## Customers Kairos Pharma does not yet sell approved products, so its near-term counterparties are not traditional end customers but rather licensors, advisors, investors, and potential development partners. If its programs advance, the eventual buyers would be hospitals, physicians, and patients through pharmaceutical commercialization channels, but today the company is primarily funded by equity investors and supported by consulting and advisory relationships. - **Equity investors** (primary) — Provide capital through IPO, PIPE, ELOC, and private financings because the company has no product revenue. - **Technology licensors** (primary) — Supply exclusive patent rights and know-how, including Cedars-licensed programs that underpin the pipeline. - **Strategic advisors and consultants** (secondary) — Support corporate strategy, investor relations, valuation, and financing execution. - **Potential pharmaceutical partners** (secondary) — May license or co-develop programs to help fund development and future commercialization. - **Future healthcare end users** (emerging) — Hospitals, physicians, and patients would be the ultimate users if candidates are approved. - Equity investors funding the company’s clinical-stage pipeline - Cedars and other IP licensors providing patented technologies - Advisors and consultants supporting capital markets and strategy - Potential pharma partners for licensing or commercialization - Future physicians, hospitals, and patients if products reach market ## Geography Kairos Pharma is headquartered in the United States and its current operating footprint is primarily U.S.-based, reflecting a domestic clinical-stage biotech model. The company also uses non-U.S. counterparties for advisory and financing support, including Canadian and Puerto Rico-based service providers, but it has not disclosed meaningful country-level revenue because it has not generated product sales. - Headquartered in the United States - Operations are centered on U.S. clinical and corporate activities - Uses Canadian advisory services for investor communications - Uses Puerto Rico-based consulting for capital markets support - No disclosed country revenue because product sales have not started ## Strategy Kairos Pharma’s strategy is to advance licensed therapeutic programs through preclinical and clinical development while building the intellectual property base needed for eventual partnering or commercialization. Near term, the company is prioritizing financing execution, advisory support, and public-company infrastructure so it can continue development without product revenue. - **Advance pipeline programs** (medium-term) — Clinical progress is the main value driver for a company with no product sales. - **Secure funding** (short-term) — The company needs external capital to fund operations until any product revenue exists. - **Pursue partnering and licensing** (medium-term) — Collaborations can provide cash, validation, and commercialization reach without full internal buildout. - **Strengthen market positioning** (short-term) — Investor communications and corporate strategy support access to capital and deal flow. - Advance licensed drug candidates through preclinical and clinical stages - Build and defend an IP portfolio around Cedars-licensed technologies - Raise capital through equity, debt, and structured financing - Pursue collaborations or licensing deals to share development risk - Expand investor relations and public-company capabilities ## Risks Kairos Pharma is exposed to the core risks of a clinical-stage biotech: it may never obtain regulatory approval, may fail to raise enough capital, and may need to dilute shareholders to fund operations. Because it has no product revenue, execution risk in development and financing is especially important, and any setback can materially affect the company’s ability to continue as a going concern. - **Funding shortfall** [critical] — The company has no sales and must finance development through equity, debt, or partnerships. - **Clinical and regulatory failure** [critical] — Drug candidates may not demonstrate safety or efficacy, or may not obtain approval. - **Shareholder dilution** [high] — Recent and future financings, including PIPEs and ELOC usage, can expand share count materially. - **Dependence on licensors and third parties** [medium] — The company relies on licensed IP, advisors, and outside service providers to progress programs. - **Going-concern pressure** [high] — Persistent losses and negative operating cash flow increase the risk of liquidity stress. - No product revenue yet, so the company depends on external financing - Clinical and regulatory failure could eliminate pipeline value - Equity raises may dilute existing shareholders significantly - Partnering may require giving up valuable rights or economics - Public-company and development costs are likely to keep rising ## Accounting The key accounting issue is that Kairos currently recognizes no revenue, so reported results are driven by R&D, G&A, and financing-related items rather than product economics. Investors should watch how the company accounts for stock-based compensation, vendor advances, warrant issuance, and any future license or collaboration arrangements, because these can materially affect expense timing and dilution. - **Revenue recognition** — Any future collaboration or license revenue may be recognized over time or at milestones depending on contract terms. - **Stock-based compensation** — Can materially increase G&A expense without cash outflow. - **Warrants and equity financing costs** — Affects dilution, financing expense, and potentially fair value measurements. - **Going-concern and liquidity estimates** — Management judgment affects disclosures and assessment of funding sufficiency. - No revenue recognition yet because no products are approved or sold - R&D expense reflects preclinical, clinical, and manufacturing development spend - G&A includes stock compensation, legal, IPO, and public-company costs - Vendor advances and consulting fees can affect expense timing - Warrants, RSUs, and equity-linked financing affect dilution and expense --- *Last updated: 2026-04-28T20:19:56.021360+00:00*